RGD Reference Report - An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Behavioral & Substance Use Disorder Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans.

Authors: Crist, Richard C  Clarke, Toni-Kim  Ang, Alfonso  Ambrose-Lanci, Lisa M  Lohoff, Falk W  Saxon, Andrew J  Ling, Walter  Hillhouse, Maureen P  Bruce, R Douglas  Woody, George  Berrettini, Wade H 
Citation: Crist RC, etal., Neuropsychopharmacology. 2013 Sep;38(10):2003-10. doi: 10.1038/npp.2013.99. Epub 2013 Apr 23.
RGD ID: 402463973
Pubmed: PMID:23612435   (View Abstract at PubMed)
PMCID: PMC3746708   (View Article at PubMed Central)
DOI: DOI:10.1038/npp.2013.99   (Journal Full-text)

Although buprenorphine and methadone are both effective treatments for opioid dependence, their efficacy can vary significantly among patients. Genetic differences may explain some of the variability in treatment outcome. Understanding the interactions between genetic background and pharmacotherapy may result in more informed treatment decisions. This study is a pharmacogenetic analysis of the effects of genetic variants in OPRD1, the gene encoding the δ-opioid receptor, on the prevalence of opioid-positive urine tests in African-Americans (n=77) or European-Americans (n=566) undergoing treatment for opioid dependence. Patients were randomly assigned to treatment with either methadone or buprenorphine/naloxone (Suboxone) over a 24-week open-label clinical trial, in which illicit opioid use was measured by weekly urinalysis. In African-Americans, the intronic SNP rs678849 predicted treatment outcome for both medications. Methadone patients with the CC genotype were less likely to have opioid-positive urine tests than those in the combined CT and TT genotypes group (relative risk (RR)=0.52, 95% confidence interval (CI)=0.44-0.60, p=0.001). In the buprenorphine treatment group, however, individuals with the CC genotype were more likely to have positive opioid drug screens than individuals in the combined CT and TT genotypes group (RR=2.17, 95% CI=1.95-2.68, p=0.008). These findings indicate that the genotype at rs678849 predicts African-American patient response to two common treatments for opioid dependence, suggesting that matching patients to treatment type based on the genotype at this locus may improve overall treatment efficacy. This observation requires confirmation in an independent population.



Disease Annotations    Click to see Annotation Detail View
RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
OPRD1Humanopiate dependence treatmentIAGP associated with African American;DNA:SNP:intron (rs678849) (human)RGD 
Oprd1Ratopiate dependence treatmentISOOPRD1 (Homo sapiens)associated with African American;DNA:SNP:intron (rs678849) (human)RGD 
Oprd1Mouseopiate dependence treatmentISOOPRD1 (Homo sapiens)associated with African American;DNA:SNP:intron (rs678849) (human)RGD 

Phenotype Annotations    Click to see Annotation Detail View

Manual Human Phenotype Annotations - RGD

Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
OPRD1HumanAddictive opioid use treatmentIAGP associated with African American;DNA:SNP:intron (rs678849) (human)RGD 
OPRD1HumanAmeliorated by exposure to medication treatmentIAGP associated with African American;DNA:SNP:intron (rs678849) (human)RGD 
OPRD1HumanPositive urine opioid test treatmentIAGP associated with African American;DNA:SNP:intron (rs678849) (human)RGD 
Objects Annotated

Genes (Rattus norvegicus)
Oprd1  (opioid receptor, delta 1)

Genes (Mus musculus)
Oprd1  (opioid receptor, delta 1)

Genes (Homo sapiens)
OPRD1  (opioid receptor delta 1)


Additional Information